Chemo-immunotherapy combination effect remains to be a great challenge due to the poor
tumor penetration of therapeutic agents that resulted from condensed extracellular matrix …

Ferroptosis can activate immune response via inducing tumor cells immunogenic cell death
(ICD), and antitumor immunity in turn boosts the efficacy of ferroptosis by excreting interferon …

The development of nanomedicine formulations to overcome the disadvantages of
traditional chemotherapeutic drugs and integrate cooperative theranostic modes still …

Prostate cancer (PCa) is a frustrating immunogenic “cold” tumor and generally receives
unsatisfied immunotherapy outcomes in the clinic. Pyroptosis is an excellent immunogenic …

Insufficient activation of the stimulator of interferon genes (STING) signaling pathway and
profoundly immunosuppressive microenvironment largely limits the effect of cancer …

The crosstalk between tumor and stroma cells is a central scenario in the tumor
microenvironment (TME). While the predominant effect of tumor cells on immune cells is …

Although conventional radiotherapy (RT) has been widely used in the clinic to treat cancer, it
often has limited therapeutic outcomes and severe toxic effects. There is still a need to …

Immunotherapy has demonstrated the potential to cure melanoma, while the current
response rate is still unsatisfactory in clinics. Extensive evidence indicates the correlation …

Immune checkpoint blockade (ICB) therapy currently considered as to be effective way to
cure cancer in clinic. However, the insufficient tumor immunogenicity and the …

Cyclic dinucleotides (CDNs), as one type of Stimulator of Interferon Genes (STING) pathway
agonist, have shown promising results for eliciting immune responses against cancer and …